High Growth Tech Stocks in Europe Featuring Three Top Picks

The European market has been experiencing a positive streak, with the pan-European STOXX Europe 600 Index posting its longest series of weekly gains since August 2012, driven by encouraging company results and resilience in defense stocks amidst uncertainties about U.S. trade policy. In this environment, identifying high growth tech stocks involves looking for companies that not only demonstrate robust financial health and innovation but also have the potential to navigate economic fluctuations effectively, making them well-positioned to capitalize on technological advancements and market opportunities.

Top 10 High Growth Tech Companies In Europe

Name	Revenue Growth	Earnings Growth	Growth Rating
Elicera Therapeutics	63.53%	97.24%	★★★★★★
Pharma Mar	23.58%	40.13%	★★★★★★
Yubico	21.27%	26.82%	★★★★★★
CD Projekt	27.11%	39.37%	★★★★★★
Ascelia Pharma	46.09%	66.93%	★★★★★★
Truecaller	20.03%	24.78%	★★★★★★
Xbrane Biopharma	73.73%	139.21%	★★★★★★
XTPL	97.45%	117.95%	★★★★★★
Skolon	29.71%	91.18%	★★★★★★
Elliptic Laboratories	49.89%	89.90%	★★★★★★

Click here to see the full list of 248 stocks from our European High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

MotorK (ENXTAM:MTRK)

Simply Wall St Growth Rating: ★★★★★☆

Overview: MotorK plc offers software-as-a-service solutions tailored for the automotive retail sector across Italy, Spain, France, Germany, and the Benelux Union with a market cap of €244.97 million.

Operations: The company generates revenue primarily through its software and programming segment, contributing €42.50 million. Its operations focus on providing SaaS solutions to the automotive retail industry in several European countries.

Despite a recent dip in its Committed Annual Recurring Revenues, MotorK remains a notable contender in the European tech landscape, with its revenue forecast to grow at an impressive 27% annually—significantly outpacing the Dutch market's 8%. This growth trajectory is bolstered by expectations of MotorK turning profitable within the next three years, showcasing a potential earnings increase of 108.44% per year. However, challenges such as outdated financial reports and a highly volatile share price temper its immediate outlook. As MotorK navigates these hurdles, its ability to innovate and adapt will be crucial in realizing its projected ascent in profitability and market position.

• Navigate through the intricacies of MotorK with our comprehensive health report here.

• Learn about MotorK's historical performance.

Bonesupport Holding (OM:BONEX)

Simply Wall St Growth Rating: ★★★★★★

Overview: Bonesupport Holding AB (publ) is an orthobiologics company that focuses on developing and commercializing injectable bio-ceramic bone graft substitutes across Europe, North America, and internationally, with a market cap of SEK25.09 billion.

Operations: Bonesupport Holding generates revenue primarily from its pharmaceuticals segment, totaling SEK898.73 million. The company specializes in injectable bio-ceramic bone graft substitutes, serving markets in Europe, North America, and beyond.

Bonesupport Holding's recent performance underscores its potential in the high-tech European sector, with a notable increase in sales to SEK 898.73 million and net income reaching SEK 133.75 million for the full year, marking substantial growth from previous figures. This surge is complemented by impressive clinical advancements; their CERAMENT products have significantly enhanced survival rates in diabetic foot ulcer treatments, boasting a survival rate of 87.5% compared to the standard treatment's 44.9%. These innovations not only highlight Bonesupport's role in advancing medical technology but also suggest robust future prospects amid growing demand for effective surgical solutions.

• Unlock comprehensive insights into our analysis of Bonesupport Holding stock in this health report.

• Review our historical performance report to gain insights into Bonesupport Holding's's past performance.

Basler (XTRA:BSL)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Basler Aktiengesellschaft specializes in developing, manufacturing, and selling digital cameras for professional users both in Germany and internationally, with a market capitalization of €244.10 million.

Operations: The company generates revenue primarily from its camera segment, which accounts for €182.31 million.

Basler AG, amidst a volatile market, is poised for significant growth with expected annual earnings surging by 113.84%. This growth trajectory is complemented by a forecasted revenue increase of 10.8% annually, outpacing the German market's 5.7%. The recent executive reshuffle, including Ines Brückel's appointment as CFO effective January 2025, aligns with Basler’s strategic focus on enhancing its digital and global marketing frameworks. This leadership enhancement and robust financial outlook underscore Basler’s potential to innovate and expand within the high-tech European landscape.

• Take a closer look at Basler's potential here in our health report.

• Evaluate Basler's historical performance by accessing our past performance report.

Taking Advantage

• Access the full spectrum of 248 European High Growth Tech and AI Stocks by clicking on this link.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com